サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1611546

放射線皮膚炎の市場規模、シェア、動向分析レポート：製品別、流通チャネル別、地域別、セグメント予測、2025年～2030年

Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Dressings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
放射線皮膚炎の市場規模、シェア、動向分析レポート：製品別、流通チャネル別、地域別、セグメント予測、2025年～2030年
出版日: 2024年11月27日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線皮膚炎市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の放射線皮膚炎市場規模は2030年までに5億5,710万米ドルに達すると予測され、市場は2025～2030年にかけてCAGR 4.0％で成長すると予測されています。

世界のがん罹患率の上昇が市場成長を促進する主要因です。がん罹患率の増加に伴い、治療計画の一環として放射線治療を受ける患者が増加しています。2024年2月、WHOは、およそ20％の人が人生のある時点でがんと診断され、男性の約9人に1人、女性の約12人に1人ががんに罹患すると予想されると報告しており、その結果、放射線皮膚炎のような副作用を管理する効果的なソリューションに対するニーズが高まっています。放射線被曝による皮膚の炎症と損傷を特徴とするこの症状には、症状の緩和と治癒の促進に焦点を当てた専門的治療が必要です。そのため、製薬会社や医療機器会社は、放射線皮膚炎に対応する革新的な治療法や製品の開発を優先しています。

がん治療中の患者ケアに対する意識の高まりと重視は、治療成績の向上に重要な役割を果たしています。医療プロバイダーは、放射線皮膚炎などの放射線治療に関連する副作用に対処する必要性をますます認識するようになっています。2024年5月のBioengineering &T ranslational Medicineの総説は、1980年代後半からのドラッグデリバリー、化粧品、組織再生におけるハイドロゲルの臨床利用を強調しています。高分子化学と製造における最近の進歩により、天然、合成、あるいは複合材料由来のハイドロゲル製品がFDAやEMAで100種類以上承認されています。これらの製品は、組織再生、顔面矯正、創傷被覆、ドラッグデリバリーなど様々な用途に使用されており、臨床検査では注射剤と非注射剤の両方が使用されています。

放射線皮膚炎市場レポートハイライト

  • 主に、入手のしやすさ、利便性の向上、経口代替品に対する優位性から、2024年の市場シェアは71.7%で局所製品セグメントが優勢を占めました。これらの製品は、患者のニーズに合わせたクリーム、ゲル、軟膏など多様な剤形があるため、大きな成長が見込まれます。
  • 流通チャネルの面では、薬局数の増加により、2024年には小売薬局セグメントが39.4%と大きなシェアを占めています。小売薬局は、病院で書かれる配合箋の大きな割合を占めています。
  • 欧州は、先進的医療インフラ、スキンケア治療に対する高い認知度、放射線治療を受ける患者が多いことから、市場シェア34.0%で世界市場を席巻しました。
  • 北米は、有望な成長機会を生み出す重要な研究開発イニシアティブにより、第2位の市場シェアを占めました。同地域の先進的な治療製品は、放射線皮膚炎産業の成長に寄与する重要な要因です。
  • 競合の特徴は、主要企業が製品上市、販売提携、戦略的パートナーシップなどの戦略を実施し、市場シェアを大きく拡大していることです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 放射線皮膚炎市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 放射線皮膚炎市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 放射線皮膚炎市場：製品別、推定・動向分析

  • 世界の放射線皮膚炎市場：製品ダッシュボード
  • 世界の放射線皮膚炎市場：製品変動分析
  • 世界の放射線皮膚炎市場規模と予測と動向分析、2018～2030年
  • 局所
    • コルチコステロイド
    • 親水性クリーム
    • 抗生物質
    • その他
  • ドレッシング
    • ハイドロゲル＆ハイドロコロイドドレッシング
    • 刺傷防止フィルムなし
    • 蜂蜜を染み込ませたガーゼ
    • シリコンコーティングドレッシング
    • その他

第5章 放射線皮膚炎市場：流通チャネル別、推定・動向分析

  • 世界の放射線皮膚炎市場：流通チャネルダッシュボード
  • 世界の放射線皮膚炎市場：流通チャネル変動分析
  • 世界の放射線皮膚炎市場規模と予測と動向分析、2018～2030年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 放射線皮膚炎市場：国、製品、流通チャネルによる地域別、推定・動向分析

  • 地域ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要メーカーによる最近の動向と影響分析
  • 企業/競合の分類
  • 主要企業の市場シェア分析、2024年
  • 企業プロファイル
    • Stratpharma AG
    • Smith &Nephew
    • Molnlycke Health Care AB
    • Derma Sciences Inc.
    • ConvaTec Inc.
    • BMG Pharma SRL
    • Acelity
    • 3M
    • Alliqua BioMedical
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 Canada radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Mexico radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 10 Mexico radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Europe radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 13 Europe radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Germany radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 15 Germany radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 UK radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 17 UK radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 France radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 19 France radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Italy radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 21 Italy radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 Spain radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 23 Spain radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Denmark radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 25 Denmark radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Sweden radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 27 Sweden radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 29 Norway radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 31 Aisa Pacific radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 China radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 34 China radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Japan radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 36 Japan radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 India radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 38 India radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 South Korea radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 40 South Korea radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Australia radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 42 Australia radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Thailand radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 44 Thailand radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Latin America radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 46 Latin America radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 47 Latin America radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Brazil radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 49 Brazil radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Argentina radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 51 Argentina radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 MEA radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 54 MEA radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 South Africa radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 56 South Africa radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 UAE radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 60 UAE radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Kuwait radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 62 Kuwait radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Radiodermatitis market: market outlook
  • Fig. 14 Radiodermatitis competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Radiodermatitis market driver impact
  • Fig. 18 Radiodermatitis market restraint impact
  • Fig. 19 Radiodermatitis market: Type movement analysis
  • Fig. 20 Radiodermatitis market: Type outlook and key takeaways
  • Fig. 21 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Hydrophilic creams market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Hydrogel & hydrocolloid dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 No sting barrier films market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Honey impregnated gauze market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Silicone coated dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Radiodermatitis market: Distribution channel movement analysis
  • Fig. 33 Radiodermatitis market: Distribution channel outlook and key takeaways
  • Fig. 34 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 North America, by country
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico key country dynamics
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 UK key country dynamics
  • Fig. 47 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Italy key country dynamics
  • Fig. 53 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Spain key country dynamics
  • Fig. 55 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark key country dynamics
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden key country dynamics
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Norway key country dynamics
  • Fig. 61 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 China key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Japan key country dynamics
  • Fig. 66 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand key country dynamics
  • Fig. 70 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Korea key country dynamics
  • Fig. 72 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Brazil key country dynamics
  • Fig. 77 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Argentina key country dynamics
  • Fig. 79 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 South Africa key country dynamics
  • Fig. 82 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 UAE key country dynamics
  • Fig. 86 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Kuwait key country dynamics
  • Fig. 88 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Market share of key market players - radiodermatitis market
目次
Product Code: GVR-1-68038-857-2

Radiodermatitis Market Growth & Trends:

The global radiodermatitis market size is expected to reach USD 557.1 million by 2030, and market is projected to grow at a CAGR of 4.0% from 2025 to 2030, according to a new report by Grand View Research, Inc.. The rising global incidence of cancer is a key factor driving the market growth. As cancer rates increase, more patients are receiving radiation therapy as part of their treatment plans. In February 2024, the WHO reported that around 20% of individuals are expected to be diagnosed with cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness, resulting in a growing need for effective solutions to manage side effects like radiodermatitis. This condition, marked by skin irritation and damage from radiation exposure, calls for specialized treatments focused on alleviating symptoms and promoting healing. Consequently, pharmaceutical and medical device companies prioritize developing innovative therapies and products to address the radiodermatitis industry.

The growing awareness and emphasis on patient care during cancer treatment play a significant role in improving outcomes. Healthcare providers are increasingly acknowledging the need to address side effects related to radiation therapy, such as radiodermatitis. The May 2024 review in Bioengineering & Translational Medicine highlighted the clinical use of hydrogels since the late 1980s across drug delivery, cosmetics, and tissue regeneration. Recent advancements in polymer chemistry and fabrication have resulted in over 100 FDA and EMA-approved hydrogel products derived from natural, synthetic, or combined materials. These products serve various purposes, including tissue regeneration, facial correction, wound dressing, and drug delivery, and include both injectable and non-injectable options in clinical trials.

Radiodermatitis Market Report Highlights:

  • The topical products segment dominated in 2024 with a market share of 71.7%, primarily due to their easy accessibility, enhanced convenience, and advantages over oral alternatives. These products are expected to experience significant growth thanks to their diverse formulations, including creams, gels, and ointments tailored to meet patient needs.
  • In terms of distribution channel, the retail pharmacies segment accounted for a substantial share of 39.4% in 2024 owing to the rising number of pharmacies. Retail pharmacies capture a large percentage of prescriptions written in the hospital.
  • Europe dominated the market globally with a market share of 34.0% due to advanced healthcare infrastructure, high awareness of skin care treatments, and a large patient population undergoing radiation therapy.
  • North America accounted for the second-largest market share due to significant R&D initiatives that have created promising growth opportunities. Advanced therapeutic products in the region are a key factor contributing to its growth in the radiodermatitis industry.
  • The competition features key players implementing strategies like product launches, distribution agreements, and strategic partnerships, which have greatly expanded their market share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution Channel
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Distribution Channel outlook
  • 2.3. Competitive Insights

Chapter 3. Radiodermatitis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer
      • 3.2.1.2. Advancements in dermatological treatments
      • 3.2.1.3. Growing awareness
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Limited availability of specialized products
  • 3.3. Radiodermatitis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Radiodermatitis Market: Product Estimates & Trend Analysis

  • 4.1. Global Radiodermatitis Market: Product Dashboard
  • 4.2. Global Radiodermatitis Market: Product Movement Analysis
  • 4.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 4.4. Topical
    • 4.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Corticosteroids
      • 4.4.2.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Hydrophilic Creams
      • 4.4.3.1. Hydrophilic creams market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Antibiotics
      • 4.4.4.1. Antibiotics market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Others
      • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Dressings
    • 4.5.1. Dressings market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.2. Hydrogel & Hydrocolloid Dressing
      • 4.5.2.1. Hydrogel & hydrocolloid dressing market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.3. No Sting Barrier Films
      • 4.5.3.1. No sting barrier films market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.4. Honey Impregnated Gauze
      • 4.5.4.1. Honey impregnated gauze market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.5. Silicone Coated Dressings
      • 4.5.5.1. Silicone coated dressings market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.6. Others
      • 4.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Global Radiodermatitis Market: Distribution Channel Dashboard
  • 5.2. Global Radiodermatitis Market: Distribution Channel Movement Analysis
  • 5.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 5.4. Hospital pharmacies
    • 5.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Retail pharmacies
    • 5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Online pharmacies
    • 5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Radiodermatitis Market: Regional Estimates & Trend Analysis by Country, Product and Distribution Channel

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Stratpharma AG
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Smith & Nephew
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Molnlycke Health Care AB
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Derma Sciences Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. ConvaTec Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. BMG Pharma S.R.L.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Acelity
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. 3M
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Alliqua BioMedical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives